Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis

Bioconjugate Chemistry
Paul McQuadeMichael J Welch

Abstract

The formation of new blood vessels (angiogenesis) is a feature common to all solid tumors. The integrin receptor alpha(V)beta(3), which is found on endothelial cells lining newly growing blood vessels at a higher density than on mature blood vessels, is being explored as a marker for tumor angiogenesis. Bitistatin, a member of the disintegrin family of polypeptides, has affinity for alpha(V)beta(3) integrins. To determine whether radiolabeled bitistatin could target tumors, its biodistribution was tested in tumor-bearing mice. For initial validation studies, (125)I-bitistatin was injected into BALB/c mice bearing EMT-6 mouse mammary carcinoma tumors, a model that is highly vascular but which lacks alpha(V)beta(3) directly on tumor cells. Tumor uptake reached maximal values (11.7 +/- 4.6 %ID/g) at 2 h. Co-injection of 200 microg of unlabeled bitistatin reduced tumor uptake 62%, suggesting that the binding of (125)I-bitistatin is receptor-mediated. This work was extended to include the beta(+)-emitting radionuclide (64)Cu, which was attached to bitistatin via 1,4,7,10-tetraazacyclododecane-N,N',N' ',N' "-tetraacetic acid (DOTA). This modification did not significantly alter receptor binding in vitro. MicroPET images obtained with...Continue Reading

References

Jan 1, 1991·The Journal of Clinical Investigation·E Ruoslahti
Aug 12, 1971·The New England Journal of Medicine·J Folkman
Jan 1, 1997·Nuclear Medicine and Biology·D W McCarthyM J Welch
Dec 10, 1999·The Journal of Clinical Investigation·E Keshet, S A Ben-Sasson
Jan 22, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Christof KnoessWolf-Dieter Heiss

❮ Previous
Next ❯

Citations

Jan 30, 2013·Journal of Medicinal Chemistry·Elena RanyukJohan E van Lier
Mar 26, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Patrick M WinterGregory M Lanza
Oct 7, 2008·Investigative Radiology·Michal LijowskiGregory M Lanza
Feb 10, 2011·Medical Physics·George C KagadisGeorge C Nikiforidis
Dec 9, 2008·International Journal of Radiation Biology·Roger W Howell
May 1, 2007·Expert Opinion on Drug Discovery·Suzanne V Smith
Feb 19, 2011·Thrombosis and Haemostasis·L Zagorchev, M J Mulligan-Kehoe
Nov 22, 2008·Methods in Enzymology·Martin TrepelWadih Arap
Jan 12, 2005·Protein Expression and Purification·Linda C Knight, Jan E Romano
Feb 6, 2007·International Journal of Cancer. Journal International Du Cancer·Grace HuGregory M Lanza
Jan 6, 2010·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Rudolph L JulianoHyun Min Kang
Mar 5, 2013·Nanomedicine : Nanotechnology, Biology, and Medicine·Aida IbricevicSteven L Brody
Jan 2, 2021·Journal of Translational Autoimmunity·Carlos A CañasGabriel J Tobón
May 15, 2007·Nuclear Medicine and Biology·Linda C KnightCezary Marcinkiewicz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

© 2021 Meta ULC. All rights reserved